Clinical Trials Logo

Macular Pigment Optical Density clinical trials

View clinical trials related to Macular Pigment Optical Density.

Filter by:
  • None
  • Page 1

NCT ID: NCT05251792 Recruiting - Glaucoma Clinical Trials

Macular Pigment Optical Density in Primary Angle-closure Disease

Start date: November 11, 2021
Phase:
Study type: Observational

Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia. Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear. Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma. This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage

NCT ID: NCT03983525 Completed - Clinical trials for Macular Pigment Optical Density

The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function

Start date: June 10, 2019
Phase: N/A
Study type: Interventional

Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old. Specific Aims: Determine if goji berry intake for 90 days, 5 times per week, will: - result in favorable changes in macular pigment optical density (MPOD), as measured using heterochromatic flicker photometry (HFP), in adults aged from 45 to 65 years old. - impact the carotenoid distribution in the skin. - will change the fermentation capacity of the gut microbiota. The investigators hypothesize that the intake of 28 grams of goji berry for 90 days, 5 days per week will significantly increase MPOD after three months, compared to baseline values. In contrast, the investigators hypothesize that a dietary supplement of lutein and zeaxanthin will not alter MPOD.

NCT ID: NCT03433885 Recruiting - Clinical trials for Macular Pigment Optical Density

Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study

Start date: January 1, 2018
Phase:
Study type: Observational

To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration

NCT ID: NCT00449917 Completed - Clinical trials for Macular Pigment Optical Density

"Visiobiane Anti-age" Effects on Vision Parameters

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the benefits of "Visiobiane Anti-age" dietary supplement on macular pigment optical density, contrast sensibility and visual acuity. Additionally, the study would like to evaluate seric variations of carotenoids and the total antioxydant capacity.